Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

TRACON Pharmaceuticals to Host Key Opinion Leader Luncheon for Investors Focused on Angiosarcoma and Prostate Cancer on December 1 in New York City


Posted on: 23 Nov 16

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that it will host a Key Opinion Leader luncheon for investors focused on the treatment of angiosarcoma and metastatic castration-resistant prostate cancer (mCRPC) at 12:00pm Eastern Time on Thursday, December 1, 2016.

This meeting will feature keynote presentations by key opinion leaders Mrinal M. Gounder, M.D., from Memorial Sloan Kettering Cancer Center (MSKCC), who will provide an overview of the unmet need in angiosarcoma and discuss current and novel approaches to therapy, and Scott T. Tagawa, M.D., M.S., from the New York Presbyterian - Weill Cornell Medical Center (WCMC), who will provide an overview of the unmet need in mCRPC and discuss current and novel approaches to therapy.

Members of the TRACON executive management team will provide an update on the Company’s developmental pipeline, including their lead compound, TRC105 (carotuximab), a novel antibody to endoglin, which is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON and the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors.  Management will also provide an overview of TRC253, a Phase 1/2-ready novel small molecule high affinity antagonist of wild type and mutated androgen receptors, including mutations associated with resistance to Xtandi® (enzalutamide).

Dr. Gounder is a practicing medical oncologist at MSKCC, specializing in the care of patients with sarcomas of soft tissue and bone. Dr. Gounder’s research interest is to further unravel the complexity of each type of sarcoma and develop new drugs in order to move away from the “one size fits all” paradigm. Currently, he is the lead investigator on several clinical trials for the treatment of sarcomas. He is also an attending physician in the Phase I Clinical Trials program, where he focuses his research on discovering and developing new compounds that are more effective in treating all solid tumors and that are less toxic for the patient. Dr. Gounder is also the Scientific Director of the Desmoid Tumor Research Foundation. Prior to arriving at MSKCC, he completed his internal medicine training at Northwestern University in Chicago, and received his M.D. from SUNY-Syracuse.

Dr. Tagawa is the Richard A. Stratton Associate Professor in Hematology and Oncology, an Associate Professor of Clinical Medicine & Urology, at Weill Cornell Medicine, and an Associate Attending Physician at New York Presbyterian – WCMC.  His research has involved clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. As the Medical Director of the Genitourinary Oncology Research Program, he leads clinical trials in the areas of prostate, kidney and bladder cancers, as well as the prevention and treatment of thrombosis with cancer. He is particularly focused on drug development and theranostics in prostate cancer. Dr. Tagawa serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology and Chair of the Clinical Study Evaluation (scientific review) Committee for cancer. He is the WCMC principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a member of the Genitourinary Committee.

The event is intended for institutional investors and sell-side analysts.  If you would like to attend in person, please contact Mac MacDonald at 212-915-2567 or via e-mail at Mac@LifeSciAdvisors.com to reserve a place.

A live webcast of the event, with slides, will be available at http://lifesci.rampard.com/20161201/reg.jsp and within the Investors section of the Company’s website at http://ir.traconpharma.com

About TRC105
TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis.

About TRC253
TRC253 is a novel, orally bioavailable small molecule that is a potent, high affinity antagonist of wild type and mutated androgen receptors, including mutations associated with resistance to Xtandi® (enzalutamide). TRC253 was discovered and initially developed by Janssen and is now under development by TRACON for the treatment of men with prostate cancer. IND-enabling studies have been completed.

About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. – TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that may display drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma.

GlobeNewswire
globenewswire.com

Last updated on: 25/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.